Brief: Apellis Pharmaceuticals Says Empaveli Provided Long-Term Control Of PNH In New Data Presented At Ash Annual Meeting

Apellis Pharmaceuticals

11/12/2023 12:16

Dec 11 (Reuters) - Apellis Pharmaceuticals Inc  APLS.O :
    * APELLIS PHARMACEUTICALS INC - EMPAVELI® (PEGCETACOPLAN)
PROVIDED
LONG-TERM CONTROL OF PNH IN NEW DATA PRESENTED AT ASH ANNUAL
MEETING
    * APELLIS PHARMACEUTICALS INC - RAPID IMPROVEMENTS IN KEY
MARKERS
OF DISEASE WERE SUSTAINED FOR UP TO THREE YEARS ACROSS ALL
ADULTS WITH PNH
    * APELLIS PHARMACEUTICALS - SAFETY PROFILE WAS CONSISTENT
WITH
PREVIOUS CLINICAL STUDY RESULTS, AND NO NEW OR UNEXPECTED SAFETY
FINDINGS WERE IDENTIFIED
    * APELLIS PHARMACEUTICALS INC - ZERO CASES OF MENINGOCOCCAL
INFECTION OBSERVED OVER THREE YEARS IN THIS ANALYSIS
    * APELLIS PHARMACEUTICALS INC - APPROXIMATELY 4.5% OF
PATIENTS
EXPERIENCED A SERIOUS ADVERSE EVENT DEEMED RELATED TO TREATMENT
WITH PEGCETACOPLAN

Source text for Eikon:  ID:nGNX7WkHb6 
Further company coverage:  APLS.O 

 ((Reuters.Briefs@thomsonreuters.com;))